Values of intensive care scores in predicting morbidity and mortality in patients treated for COVID-19 pneumonia

Q3 Medicine
Hale Kefeli Çelik, Z. Doğanay, Ramazan BURAK FERLİ
{"title":"Values of intensive care scores in predicting morbidity and mortality in patients treated for COVID-19 pneumonia","authors":"Hale Kefeli Çelik, Z. Doğanay, Ramazan BURAK FERLİ","doi":"10.52142/omujecm.39.4.43","DOIUrl":null,"url":null,"abstract":"Some of the patients with COVID-19 pneumonia are followed up in intensive care units (ICU). This study aimed to determine the success of intensive care scores used in patients followed up in the ICU with the diagnosis of COVID-19 pneumonia in predicting morbidity and mortality. This retrospective study included patients treated for COVID-19 pneumonia in the ICUs of Samsun Training and Research Hospital. We used the patients' demographic characteristics, vital signs, arterial blood gas values, radiological imaging, and laboratory data by using the hospital database and patient files. Group I was composed of alive patients, while Group II was of dead ones. A total of 75 patients were included in the study, of which 34 (45.3%) were female and 41 (54.7%) were male. The median length of intensive care stay was 8 (5-15) days in Group I patients and 5 (2-8) days in Group II patients, which was higher in alive patients (p=0.004). Radiological involvement was present in 93.3% (n=70) of the patients, and involvement was observed in both lungs in 77.3% (n=58). We observed complications in 54.7% (n=41) of the patients, whereas the incidence of complications was 20% in Group I and 72% in Group II, which was statistically significant (p<0.001). APACHE II, PSI, SOFA, qSOFA, SMART-COP, CURB65, A-DROP and NEWS2 scores were statistically significantly higher in patients who died, whereas APACHE II, SOFA, qSOFA, and SMART-COP scores were more successful in predicting morbidity. It is vital to predict the mortality risk early in patients with COVID-19 pneumonia followed up in intensive care units. Among the scoring systems, APACHE II, PSI, SOFA, qSOFA, SMART-COP, CURB65, A-DROP, and NEWS2 can be used safely to predict mortality. Copyright © 2022 Ondokuz Mayis Universitesi. All rights reserved.","PeriodicalId":38819,"journal":{"name":"Tokai Journal of Experimental and Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tokai Journal of Experimental and Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52142/omujecm.39.4.43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Some of the patients with COVID-19 pneumonia are followed up in intensive care units (ICU). This study aimed to determine the success of intensive care scores used in patients followed up in the ICU with the diagnosis of COVID-19 pneumonia in predicting morbidity and mortality. This retrospective study included patients treated for COVID-19 pneumonia in the ICUs of Samsun Training and Research Hospital. We used the patients' demographic characteristics, vital signs, arterial blood gas values, radiological imaging, and laboratory data by using the hospital database and patient files. Group I was composed of alive patients, while Group II was of dead ones. A total of 75 patients were included in the study, of which 34 (45.3%) were female and 41 (54.7%) were male. The median length of intensive care stay was 8 (5-15) days in Group I patients and 5 (2-8) days in Group II patients, which was higher in alive patients (p=0.004). Radiological involvement was present in 93.3% (n=70) of the patients, and involvement was observed in both lungs in 77.3% (n=58). We observed complications in 54.7% (n=41) of the patients, whereas the incidence of complications was 20% in Group I and 72% in Group II, which was statistically significant (p<0.001). APACHE II, PSI, SOFA, qSOFA, SMART-COP, CURB65, A-DROP and NEWS2 scores were statistically significantly higher in patients who died, whereas APACHE II, SOFA, qSOFA, and SMART-COP scores were more successful in predicting morbidity. It is vital to predict the mortality risk early in patients with COVID-19 pneumonia followed up in intensive care units. Among the scoring systems, APACHE II, PSI, SOFA, qSOFA, SMART-COP, CURB65, A-DROP, and NEWS2 can be used safely to predict mortality. Copyright © 2022 Ondokuz Mayis Universitesi. All rights reserved.
重症监护评分在预测COVID-19肺炎患者发病率和死亡率中的价值
部分COVID-19肺炎患者在重症监护病房(ICU)接受随访。本研究旨在确定重症监护评分在预测COVID-19肺炎在ICU随访患者的发病率和死亡率方面的成功。本回顾性研究纳入了在三星培训研究医院重症监护室治疗的COVID-19肺炎患者。通过医院数据库和患者档案,我们使用了患者的人口统计学特征、生命体征、动脉血气值、放射成像和实验室数据。第一组为在世患者,第二组为死亡患者。共纳入75例患者,其中女性34例(45.3%),男性41例(54.7%)。重症监护时间中位数I组为8(5-15)天,II组为5(2-8)天,在世患者中位数更高(p=0.004)。93.3% (n=70)的患者表现为影像学受累,77.3% (n=58)的患者表现为双肺受累。我们观察到54.7% (n=41)的患者出现并发症,而I组的并发症发生率为20%,II组为72%,差异有统计学意义(p<0.001)。APACHE II、PSI、SOFA、qSOFA、SMART-COP、CURB65、A-DROP和NEWS2评分在死亡患者中有统计学意义上较高,而APACHE II、SOFA、qSOFA和SMART-COP评分在预测发病率方面更成功。对重症监护病房随访的COVID-19肺炎患者进行早期死亡风险预测至关重要。在评分系统中,APACHE II、PSI、SOFA、qSOFA、SMART-COP、CURB65、A-DROP、NEWS2可安全用于预测死亡率。版权所有©2022 Ondokuz Mayis Universitesi。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
32
期刊介绍: The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信